A Prospective Cohort of Obinutuzumab and Chlorambucil (GC) Chemotherapy for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia Including Next- Generation Sequencing (NGS)-Based Assessment
This study is prospective, open-label, single arm observational study to assess efficacy of obinutuzumab plus chlorambucil (GC) chemotherapy in treatment naïve CLL, and prognostic impact of genetic alterations for CLL using NGS.
Chronic Lymphocytic Leukemia
DRUG: Obinutuzumab
Overall response rate, iwCLL criteria, 3 years
Complete remission rate, No evidence of disease at the time of tumor assessment by NGS method, 3 years|Progression free survival, the time from first dose to documented disease progression, 3 years|Overall survival, the time from first dose to death from any cause, 3 years
This study is prospective, open-label, single arm observational study to assess efficacy of obinutuzumab plus chlorambucil (GC) chemotherapy in treatment naïve CLL, and prognostic impact of genetic alterations for CLL using NGS.